Dr. Amjad Alhalaweh
Amjad is a formulation scientist at Recipharm’s development facility in Uppsala, Sweden. He is responsible for developing solutions for complex formulation challenges for both newly discovered compounds and existing drugs, along with finding new, cost-effective approaches for formulation design.
He has specific expertise in the development of liquid formulations through crystallisation, solid-state characterisation and solid form screening and selection. He also delivers lectures at Uppsala University on the formulation of poorly soluble compounds.An active member of several professional bodies including the Controlled Release Society, the American Association of Pharmaceutical Science and the Swedish Association of Pharmaceutical Science, Amjad is also a registered pharmacist with the Syrian Pharmaceutical Association.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.For more information on Recipharm and our services, please visit www.recipharm.com